Cytek Biosciences to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Cytek Biosciences (Nasdaq: CTKB), a leading cell analysis solutions company, has announced its participation in three upcoming investor conferences:

1. UBS Genomic Medicine Summit in Dana Point, CA on August 14, 2024. Cytek will join a panel discussion titled 'Expanding Horizons - Spatial and Beyond' at 2:00 p.m. PT / 5:00 p.m. ET.

2. Wells Fargo Healthcare Conference in Boston, MA on September 4-5, 2024. The company will participate in investor 1x1 meetings.

3. Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY on September 6, 2024. Cytek will participate in a fireside chat at 4:45 a.m. PT / 7:45 a.m. ET.

Live and archived webcasts of these presentations will be available on the 'Investors' section of Cytek's website at investors.cytekbio.com.

FREMONT, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences.

• UBS Genomic Medicine Summit in Dana Point, CA
  Panel discussion: Expanding Horizons - Spatial and Beyond on Wednesday, August 14, 2024, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time

• Wells Fargo Healthcare Conference in Boston, MA
  Participating in investor 1x1 meetings on Wednesday and Thursday, September 4-5, 2024

• Morgan Stanley 22^nd Annual Global Healthcare Conference in New York, NY
  Fireside chat on September 6, 2024, at 4:45 a.m. Pacific Time / 7:45 a.m. Eastern Time

Interested parties may access a live and archived webcast of these presentations on the “Investors” section of the company website at: investors.cytekbio.com.

About Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s FSP platform includes its core instruments, the Cytek Aurora™ and Northern Lights™ systems; its cell sorter, the Cytek Aurora™ CS; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle (ESP™) detection technology, the flow cytometer and imaging products under the Amnis® and Guava® brands; and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.

Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use in China and the European Union).

Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, ESP, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc.

In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.

Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com

Investor Contact:
Paul Goodson
Head of Investor Relations
pgoodson@cytekbio.com

FAQ

What investor conferences will Cytek Biosciences (CTKB) attend in August and September 2024?

Cytek Biosciences will attend the UBS Genomic Medicine Summit in Dana Point, CA on August 14, the Wells Fargo Healthcare Conference in Boston, MA on September 4-5, and the Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY on September 6, 2024.

When is Cytek Biosciences (CTKB) participating in the UBS Genomic Medicine Summit?

Cytek Biosciences will participate in the UBS Genomic Medicine Summit on Wednesday, August 14, 2024, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time in Dana Point, CA.

What type of presentation will Cytek Biosciences (CTKB) give at the Morgan Stanley Healthcare Conference?

Cytek Biosciences will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024, at 4:45 a.m. Pacific Time / 7:45 a.m. Eastern Time in New York, NY.

How can investors access Cytek Biosciences' (CTKB) conference presentations?

Investors can access live and archived webcasts of Cytek Biosciences' conference presentations on the 'Investors' section of the company website at investors.cytekbio.com.